Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

TopQ Cut-off Determination Study For 3D-OCT 1 Maestro and 3D OCT-2000

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02203981
Recruitment Status : Completed
First Posted : July 30, 2014
Last Update Posted : October 23, 2014
Sponsor:
Information provided by (Responsible Party):
Topcon Medical Systems, Inc.

Brief Summary:
To determine optimal cut-off value for the TopQ cut-off on the Maestro and 3D OCT-2000.

Condition or disease
Healthy

Layout table for study information
Study Type : Observational
Actual Enrollment : 12 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: TopQ Cut-off Determination Study For 3D-OCT 1 Maestro and 3D OCT-2000
Study Start Date : January 2014
Actual Primary Completion Date : July 2014
Actual Study Completion Date : August 2014



Primary Outcome Measures :
  1. Retinal Thickness [ Time Frame: Day 1 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects that have no known ocular pathologies
Criteria

Inclusion Criteria:

  • No known ocular pathologies

Exclusion Criteria:

  • Any known ocular pathologies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02203981


Locations
Layout table for location information
United States, New Jersey
Topcon Medical Systems, Inc.
Oakland, New Jersey, United States, 07436
Sponsors and Collaborators
Topcon Medical Systems, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Sunni Patel, PhD Topcon Corporation
Layout table for additonal information
Responsible Party: Topcon Medical Systems, Inc.
ClinicalTrials.gov Identifier: NCT02203981    
Other Study ID Numbers: TopQ_Maestro_OCT2000_001
First Posted: July 30, 2014    Key Record Dates
Last Update Posted: October 23, 2014
Last Verified: October 2014
Keywords provided by Topcon Medical Systems, Inc.:
normal Eyes